Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV

Journal of Virology

Volumn 85, Issue 2, 2011, Pages 697-704

  Wirblich, Christoph ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS GLYCOPROTEIN;

ARTICLE; CODON; GENE MUTATION; GENETIC VARIABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES VIRUS; VIRUS GENE; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, VIRAL; CELL LINE; CODON; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLYCOPROTEINS; MALE; MICE; MOLECULAR SEQUENCE DATA; NEURONS; RABIES; RABIES VIRUS; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS;

MUS; RABIES VIRUS;

EID: 78650659163     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01309-10     Document Type: Article

References (45)

1. Brzózka, K., S. Finke, and K. K. Conzelmann. 2006. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol. 80:2675-2683.
2. Cenna, J., M. Hunter, G. S. Tan, A. B. Papaneri, E. P. Ribka, M. J. Schnell, P. A. Marx, and J. P. McGettigan. 2009. Replication-deficient rabies virusbased vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 200:1251-1260.
3. Chelbi-Alix, M. K., A. Vidy, J. El Bougrini, and D. Blondel. 2006. Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies. J. Interferon Cytokine Res. 26:271-280.
4. Coleman, J. R., D. Papamichail, S. Skiena, B. Futcher, E. Wimmer, and S. Mueller. 2008. Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784-1787.
5. Cox, J. H., B. Dietzschold, and L. G. Schneider. 1977. Rabies virus glycoprotein. II. Biological and serological characterization. Infect. Immun. 16: 54-759.
6. Dietzschold, B., M. Gore, P. Casali, Y. Ueki, C. E. Rupprecht, A. L. Notkins, and H. Koprowski. 1990. Biological characterization of human monoclonal antibodies to rabies virus. J. Virol. 64:3087-3090.
7. Dudek, T., and D. M. Knipe. 2006. Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-239.
8. Etessami, R., K. K. Conzelmann, B. Fadai-Ghotbi, B. Natelson, H. Tsiang, and P. E. Ceccaldi. 2000. Spread and pathogenic characteristics of a Gdeficient rabies virus recombinant: an in vitro and in vivo study. J. Gen. Virol. 81:2147-2153.
9. Faber, M., M. L. Faber, A. Papaneri, M. Bette, E. Weihe, B. Dietzschold, and M. J. Schnell. 2005. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J. Virol. 79:14141-14148.
10. Faber, M., R. Pulmanausahakul, S. S. Hodawadekar, S. Spitsin, J. P. McGettigan, M. J. Schnell, and B. Dietzschold. 2002. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 76:3374-3381.
11. Freuling, C., A. Vos, N. Johnson, A. R. Fooks, and T. Muller. 2009. Bat rabies-a Gordian knot? Berl. Munch. Tierarztl. Wochenschr. 122:425-433.
12. Gao, W., A. Rzewski, H. Sun, P. D. Robbins, and A. Gambotto. 2004. Up-Gene: application of a web-based DNA codon optimization algorithm. Biotechnol. Prog. 20:443-448.
13. Gomme, E. A., E. J. Faul, P. Flomenberg, J. P. McGettigan, and M. J. Schnell. 2010. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 84:2820-2831.
14. Hemachudha, T. 1994. Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr. Top. Microbiol. Immunol. 187:121-143.
15. Inoue, K., Y. Shoji, I. Kurane, T. Iijima, T. Sakai, and K. Morimoto. 2003. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 107:229-236.
16. Ito, N., G. W. Moseley, D. Blondel, K. Shimizu, C. L. Rowe, Y. Ito, T. Masatani, K. Nakagawa, D. A. Jans, and M. Sugiyama. 2010. The role of interferon-antagonist activity of rabies virus phosphoprotein in viral pathogenicity. J. Virol. 84:6699-6710.
17. Ito, N., M. Sugiyama, K. Yamada, K. Shimizu, M. Takayama-Ito, J. Hosokawa, and N. Minamoto. 2005. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol. 49:971-979.
18. Le Mercier, P., Y. Jacob, K. Tanner, and N. Tordo. 2002. A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome. J. Virol. 76:2024-2027.
19. McGettigan, J. P., K. Naper, J. Orenstein, M. Koser, P. M. McKenna, and M. J. Schnell. 2003. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 77:10889-10899.
20. Mebatsion, T., M. Konig, and K. K. Conzelmann. 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 84:941-951.
21. Morimoto, K., H. D. Foley, J. P. McGettigan, M. J. Schnell, and B. Dietzschold. 2000. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. Neurovirol. 6:373-381.
22. Morimoto, K., D. C. Hooper, H. Carbaugh, Z. F. Fu, H. Koprowski, and B.Dietzschold. 1998. Rabies virus quasispecies: implications for pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 95:3152-3156.
23. Morimoto, K., D. C. Hooper, S. Spitsin, H. Koprowski, and B. Dietzschold.1999. Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J. Virol. 73:510-518.
24. Morimoto, K., Y. Shoji, and S. Inoue. 2005. Characterization of P genedeficient rabies virus: propagation, pathogenicity and antigenicity. Virus Res. 111:61-67.
25. Mrak, R. E., and L. Young. 1994. Rabies encephalitis in humans: pathology, pathogenesis and pathophysiology. J. Neuropathol. Exp. Neurol. 53:1-10.
26. Mueller, S., D. Papamichail, J. R. Coleman, S. Skiena, and E. Wimmer. 2006. Reduction of the rate of poliovirus protein synthesis through largescale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80:9687-9696.
27. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 108:193-199.
28. Pulmanausahakul, R., M. Faber, K. Morimoto, S. Spitsin, E. Weihe, D. C. Hooper, M. J. Schnell, and B. Dietzschold. 2001. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J. Virol. 75:10800-10807.
29. Rupprecht, C. E., J. Barrett, D. Briggs, F. Cliquet, A. R. Fooks, B. Lumlertdacha, F. X. Meslin, T. Muler, L. H. Nel, C. Schneider, N. Tordo, and A. I. Wandeler. 2008. Can rabies be eradicated? Dev. Biol. (Basel) 131:95-121.
30. Rupprecht, C. E., C. A. Hanlon, and D. Slate. 2006. Control and prevention of rabies in animals: paradigm shifts. Dev. Biol. (Basel) 125:103-111.
31. Rupprecht, C. E., C. A. Hanlon, and D. Slate. 2004. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev. Biol. (Basel) 119:173-184.
32. Schnell, M. J., J. P. McGettigan, C. Wirblich, and A. Papaneri. 2010. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 8:51-61.
33. Schnell, M. J., G. S. Tan, and B. Dietzschold. 2005. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J. Neurovirol. 11:76-81.
34. Shimizu, K., N. Ito, T. Mita, K. Yamada, J. Hosokawa-Muto, M. Sugiyama, and N. Minamoto. 2007. Involvement of nucleoprotein, phosphoprotein, and matrix protein genes of rabies virus in virulence for adult mice. Virus Res. 123:154-160.
35. Shoji, Y., S. Inoue, K. Nakamichi, I. Kurane, T. Sakai, and K. Morimoto. 2004. Generation and characterization of P gene-deficient rabies virus. Virology 318:295-305.
36. Takayama-Ito, M., N. Ito, K. Yamada, M. Sugiyama, and N. Minamoto. 2006. Multiple amino acids in the glycoprotein of rabies virus are responsible for pathogenicity in adult mice. Virus Res. 115:169-175.
37. Tordo, N., A. Foumier, C. Jallet, M. Szelechowski, B. Klonjkowski, and M. Eloit. 2008. Canine adenovirus based rabies vaccines. Dev. Biol. (Basel) 131:467-476.
38. Vidy, A., M. Chelbi-Alix, and D. Blondel. 2005. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J. Virol. 79:14411-14420.
39. Vidy, A., J. El Bougrini, M. K. Chelbi-Alix, and D. Blondel. 2007. The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. J. Virol. 81:4255-4263.
40. Weyer, J., C. E. Rupprecht, and L. H. Nel. 2009. Poxvirus-vectored vaccines for rabies-a review. Vaccine 27:7198-7201.
41. WHO. 2005. WHO expert consultation on rabies, p. 1-88 and back cover. WHO technical report series, no. 931. WHO Press, Geneva, Switzerland.
42. Wiktor, T. J., E. Gyorgy, D. Schlumberger, F. Sokol, and H. Koprowski. 1973. Antigenic properties of rabies virus components. J. Immunol. 110:269-276.
43. Wirblich, C., G. S. Tan, A. Papaneri, P. J. Godlewski, J. M. Orenstein, R. N. Harty, and M. J. Schnell. 2008. PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity. J. Virol. 82:9730-9738.
44. Yamada, K., N. Ito, M. Takayama-Ito, M. Sugiyama, and N. Minamoto. 2006. Multigenic relation to the attenuation of rabies virus. Microbiol. Immunol. 50:25-32.
45. Yan, X., M. Prosniak, M. T. Curtis, M. L. Weiss, M. Faber, B. Dietzschold, and Z. F. Fu. 2001. Silver-haired bat rabies virus variant does not induce apoptosis in the brain of experimentally infected mice. J. Neurovirol. 7:518-527.